Free shipping on all orders over $ 500

Labetuzumab govitecan

Cat. No. M24697
Labetuzumab govitecan Structure
Synonym:

IMMU 130 hMN-14-SN-38

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer.

Chemical Information
CAS Number 1469876-18-3
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Diana C DeLucia, et al. Clin Cancer Res. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drυg Conjugate in Neuroendocrine Prostate Cancer

[2] Wenjuan Dong, et al. Eur J Med Chem. Antibody-drυg conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan

[3] Robert M Sharkey, et al. Mol Cancer Ther. Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drυg Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)

[4] Manjulika Das. Lancet Oncol. Labetuzumab govitecan in metastatic colorectal cancer

[5] Efrat Dotan, et al. J Clin Oncol. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drυg Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

Related Drug-Linker Conjugates for ADC Products
SC-VC-PAB-MMAE

SC-VC-PAB-MMAE is part of a drug-linker conjugate for ADC (ADC) with anticancer activity, which consists of MMAE (a tubulin inhibitor) linked to a cleavable SC-VC-PAB linker.

DBCO-(PEG)3-VC-PAB-MMAE

DBCO-(PEG)3-vc-PAB-MMAE is an active molecule coupler (drug-linker conjugate for ADC) consisting of auristatin E attached to a DBCO-(PEG)3-vc-PAB connector. It can be used for cancer research. In addition, DBCO-(PEG)3-vc-PAB-MMAE is a click chemistry that contains a DBCO moiety and can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing an Azide moiety.

PB038

PB038 is a drug-liker containing a PEG unit and a cleavable linker attached to Exatecan.

Val-Ala-PAB-MMAE

Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE.

Val-Ala-PABC-Exatecan

Val-Ala-PABC-Exatecan is a Drug-Linker Conjugates for ADC, consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor).

  Catalog
Abmole Inhibitor Catalog




Keywords: Labetuzumab govitecan, IMMU 130 hMN-14-SN-38 supplier, Drug-Linker Conjugates for ADC, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.